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Summary
Background Maternal obesity is associated with increased birthweight, and obesity and premature mortality in adult 
oﬀ spring. The mechanism by which maternal obesity leads to these outcomes is not well understood, but maternal 
hyperglycaemia and insulin resistance are both implicated. We aimed to establish whether the insulin sensitising 
drug metformin improves maternal and fetal outcomes in obese pregnant women without diabetes.
Methods We did this randomised, double-blind, placebo-controlled trial in antenatal clinics at 15 National Health 
Service hospitals in the UK. Pregnant women (aged ≥16 years) between 12 and 16 weeks’ gestation who had a BMI of 
30 kg/m² or more and normal glucose tolerance were randomly assigned (1:1), via a web-based computer-generated 
block randomisation procedure (block size of two to four), to receive oral metformin 500 mg (increasing to a maximum 
of 2500 mg) or matched placebo daily from between 12 and 16 weeks’ gestation until delivery of the baby. Randomisation 
was stratiﬁ ed by study site and BMI band (30–39 vs ≥40 kg/m²). Participants, caregivers, and study personnel were 
masked to treatment assignment. The primary outcome was Z score corresponding to the gestational age, parity, and 
sex-standardised birthweight percentile of liveborn babies delivered at 24 weeks or more of gestation. We did analysis 
by modiﬁ ed intention to treat. This trial is registered, ISRCTN number 51279843.
Findings Between Feb 3, 2011, and Jan 16, 2014, inclusive, we randomly assigned 449 women to either placebo (n=223) 
or metformin (n=226), of whom 434 (97%) were included in the ﬁ nal modiﬁ ed intention-to-treat analysis. Mean 
birthweight at delivery was 3463 g (SD 660) in the placebo group and 3462 g (548) in the metformin group. The 
estimated eﬀ ect size of metformin on the primary outcome was non-signiﬁ cant (adjusted mean diﬀ erence –0·029, 
95% CI –0·217 to 0·158; p=0·7597). The diﬀ erence in the number of women reporting the combined adverse 
outcome of miscarriage, termination of pregnancy, stillbirth, or neonatal death in the metformin group (n=7) versus 
the placebo group (n=2) was not signiﬁ cant (odds ratio 3·60, 95% CI 0·74–17·50; p=0·11).
Interpretation Metformin has no signiﬁ cant eﬀ ect on birthweight percentile in obese pregnant women. Further 
follow-up of babies born to mothers in the EMPOWaR study will identify longer-term outcomes of metformin in this 
population; in the meantime, metformin should not be used to improve pregnancy outcomes in obese women 
without diabetes.
Funding The Eﬃ  cacy and Mechanism Evaluation (EME) Programme, a Medical Research Council and National 
Institute for Health Research partnership.
Copyright © Chiswick et al. Open Access article distributed under the terms of CC BY.
Introduction
The adverse eﬀ ects of maternal obesity on short- 
term pregnancy complications include pre-eclampsia,1 
caesarean section, increased duration of maternal and 
neonatal hospital stay, maternal haemorrhage, infant 
mortality,2 and stillbirth.3 Maternal obesity during 
pregnancy is also associated with raised birthweight and 
neonatal fat mass.3–4
Accumulating data suggest that maternal obesity 
might predispose oﬀ spring to later life obesity, with high 
birthweight being a marker for increased risk. 
Correlations between high birthweight and adult obesity 
have been reported in large epidemiological studies,5,6 a 
systematic review,7 and a validated prediction model.8 The 
rapid rise in the prevalence of both high birthweight9 and 
maternal obesity mean that their links with later life 
obesity are a major concern. Indeed, in a record linkage 
study,10 we showed that maternal obesity was associated 
with a 35% increase in the hazard of all-cause oﬀ spring 
mortality in adulthood, even after adjustment for 
confounders. As such, an eﬀ ective intervention applied 
during pregnancy could have a major eﬀ ect on 
interruption of the cycle of maternal obesity and oﬀ spring 
obesity and ill health, thus helping to reverse the upward 
secular trend in obesity prevalence.
Much evidence implicates insulin resistance (ie, when a 
deﬁ ned concentration of insulin does not eﬀ ect a 
predictable metabolic response) and hyperglycaemia as 
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the mechanism by which maternal obesity causes 
excessive neonatal birthweight. Obese pregnant women 
are signiﬁ cantly more insulin resistant and hyper-
glycaemic than are pregnant women of a normal weight,11 
and several large studies, including the Camden study12 
and the HAPO study,13 show a positive association 
between high glucose concentrations and macrosomia, 
even at glucose concentrations regarded as normal during 
pregnancy. Additionally, a Cochrane review protocol14 has 
outlined additional potential beneﬁ ts on mother and baby 
of metformin in obese pregnant women. 
In view of these ﬁ ndings, we did this EMPOWaR study15 
to test the hypothesis that the insulin sensitising drug 
metformin would reduce birthweight when given to obese 
women during pregnancy. On the basis of ﬁ ndings from 
other epidemiological studies5,6,16 a reduction in birthweight 
would be expected to result in a reduction in future life risk 
of obesity and metabolic syndrome in the oﬀ spring.
Methods
Study design and participants
We did this randomised, double-blind, placebo-controlled 
trial in antenatal clinics at 15 National Health Service 
(NHS) hospitals in the UK. Eligible women were aged 
16 years or older, had a BMI of 30 kg/m² or more, and 
were between 12 and 16 weeks’ gestation. We excluded 
non-white women and those with: pre-existing diabetes; 
gestational diabetes in a previous pregnancy; gestational 
diabetes diagnosed in the index pregnancy before 
randomisation; systemic disease at the time of trial entry 
(requiring either regular drugs or treatment with 
systemic corticosteroids in the past 3 months); previous 
delivery of a baby smaller than the 3rd percentile for 
weight; previous pregnancy with pre-eclampsia 
prompting delivery before 32 weeks’ gestation; known 
hypersensitivity to metformin hydrochloride or any of 
the excipients; known liver failure; known renal failure; 
acute disorders at the time of trial entry with the potential 
to change renal function, such as dehydration suﬃ  cient 
to require intravenous infusion, severe infection, shock, 
intravascular administration of iodinated contrast agents, 
or acute or chronic diseases that might cause tissue 
hypoxia (eg, cardiac or respiratory failure, recent 
myocardial infarction, hepatic insuﬃ  ciency, acute alcohol 
intoxication, or alcoholism); lactating women; and 
women with multiple pregnancy.
The study was approved by the Scotland A research 
ethics committee (reference number 10/MRE00/12) and 
the Medicines and Healthcare products Regulatory Agency 
(EudraCT number 2009-017134-47). All participants 
provided written information consent. The protocol has 
been published elsewhere15 and is available online.
Randomisation and masking
We randomly assigned participants (1:1), via a web-based 
computer-generated block randomisation procedure (block 
size of two to four), to receive metformin or placebo. 
Randomisation was stratiﬁ ed by study site and BMI band 
(30–39 vs ≥40 kg/m²). Participants, caregivers, and study 
personnel were masked to treatment assignment. Members 
of the independent Data Monitoring Committee had access 
to unmasked data reports, but had no contact with study 
participants.
Procedures
Demographics, medical history, and maternal anthro-
pometry were recorded at baseline. A formal 75 g oral 
glucose tolerance test was done in addition to screening for 
liver and renal function. We excluded participants with 
impaired renal function (urea >6·6 mmol/L, creatinine 
>85 μmol/L, sodium >145 mmol/L, potassium 
>5·0 mmol/L), or liver function (bilirubin >16 μmol/L, 
alanine transferase >60 IU/L), or with abnormal lactate 
(according to local laboratory reference range) or gestational 
diabetes deﬁ ned by WHO criteria (fasting glucose 
≥7·0 mmol/L and 2 h glucose ≥7·8 mmol/L), or any other 
local hospital criteria (eg, International Association of 
Diabetes and Pregnancy Study Groups [IADPSG]17).
For the protocol see
http://www.nets.nihr.ac.
uk/__data/assets/pdf_
ﬁ le/0008/52883/PRO-08-246-
09.pdf
Research in context
Evidence before this study
We searched Medline between Jan 1, 1980, and April 30, 2015, 
with the terms “metformin”, “pregnancy”, “birthweight”, and 
“randomised trial”. Four reports were identiﬁ ed: three focused 
on women with gestational diabetes (ie, a diﬀ erent study 
population to our study) and one was the protocol for the 
EMPOWaR study. Birthweight was a secondary outcome in 
one study (Vanky et al, 2010), in which pregnant women with 
a history of polycystic ovary syndrome were randomly 
assigned to receive metformin or placebo.
Added value of this study
To our knowledge, this is the ﬁ rst placebo-controlled study 
designed to establish the eﬀ ect of metformin on birthweight in 
obese pregnant women.
Implications of all the available evidence
Metformin given to normally glucose tolerant obese pregnant 
women from 12– 16 weeks’ gestation until delivery has no 
signiﬁ cant eﬀ ect on gestational age, parity, or sex-standardised 
birthweight percentile. Further follow-up of babies born to 
mothers in the EMPOWaR study will identify longer-term 
outcomes of metformin in this population. In the meantime, 
metformin should not be used to improve pregnancy outcomes 
in obese women without diabetes. 
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Participants received oral metformin 500 mg or 
matched placebo tablets, in a dose of up to ﬁ ve tablets 
daily in two to three divided doses. Treatment was 
initiated at 12–16 weeks’ gestation and continued until 
delivery of the baby. Treatment started at one 500 mg 
tablet once a day at week 1, and escalated by one tablet a 
day each week over 5 weeks, to reach either the maximum 
tolerable dose or the maximum permitted dose of 
2500 mg, whichever was lower. In the case of side-eﬀ ects, 
participants were advised to reduce the current dose to 
that of the previous week, and wait for 1 week before 
increasing the dose again. The local investigator was 
allowed to change the treatment regimen at their 
discretion, as long as the maximum daily dose did not 
exceed 2500 mg in three divided doses. Participants were 
asked to keep a diary of drug intake and to bring all drugs 
to each study visit to monitor compliance.
Randomised participants were reviewed face to face or by 
telephone at 18–20, 28, 36, and 40 weeks’ gestation; around 
the time of delivery; and 3 months postnatally. Pregnancy 
complications were recorded and women were asked to 
complete a side-eﬀ ect questionnaire at each review visit 
until delivery. Maternal anthropometry was repeated at 
36 weeks’ gestation and 3 months postnatally. The glucose 
tolerance test was repeated at 28 and 36 weeks’ gestation, 
and blood was stored for measurement of inﬂ ammatory 
and metabolic indices. The protocol recommended that 
women who developed gestational diabetes should be 
given insulin whilst maintaining study treatment and 
blinding. The baby’s weight and anthropometry were 
recorded at delivery and at the 3 month postnatal visit.
Outcomes
The primary outcome was Z score corresponding to the 
gestational age, parity, and sex-standardised birthweight 
percentile of liveborn babies delivered at 24 or more weeks’ 
gestation. The main secondary outcome was maternal 
insulin resistance at 36 weeks’ gestation. Other secondary 
outcomes included maternal fasting glucose and insulin 
and 2 h glucose at 36 weeks; maternal anthropometry 
and body composition; baby anthropometry and body 
composition; maternal inﬂ ammatory and metabolic 
outcomes at 36 weeks, including C-reactive protein (CRP), 
cholesterol, HDL, LDL, triglycerides, interleukin (IL)-6, 
leptin, serum cortisol, non-esteriﬁ ed fatty acids, and the 
ratio of plasminogen activator inhibitor 1 to 2; incidence of 
low birthweight percentile (<3rd and <10th); incidence of 
other adverse maternal and neonatal outcomes, including 
maternal symptoms; maternal plasma metformin 
concentration to explore tablet taking in the metformin 
group; and the maternal metabolic (fasting glucose and 
insulin and 2 h glucose) and inﬂ ammatory markers at 
28 weeks. The methods for detection of the blood analytes 
have been described elsewhere.15 Secondary mechanistic 
outcomes as outlined in the published protocol15 were 
obtained in a subset of participants and will be reported 
elsewhere.
We made some changes to the protocol after recruit-
ment began, but before generation of the statistical 
analysis plan, publication of the protocol,15 and unmasking 
and analysis. Speciﬁ cally, maternal insulin resistance at 
36 weeks’ gestation was originally a co-primary outcome, 
but was relegated to a secondary outcome when a 
substantial proportion of participants did not provide a 
blood sample at 36 weeks. Additionally, we used patient 
self-reporting of tablet taking to establish treatment 
compliance and inform the per-protocol analysis. 
Statistical analysis
We calculated that a sample size of 143 women in each 
group would provide 80% power, and a sample size of 
163 women in each group would provide 85% power, to 
Figure: Trial proﬁ le
*Change in eligibility from screening of notes to recruitment visit (unable to arrange recruitment visit before 
16 weeks [n=26]), recruitment stopped before screening appointment (n=14), miscarriage (n=2), moved out of 
area (n=1), unable to provide informed consent because of diﬃ  culties with spoken English (n=5), own doctor or 
midwife advised against participation (n=4), duplicate note screening number issued in error (n=4). †3 months 
after birth.
92 did not reach last follow up†
2 neonatal death
65 did not attend
16 declined to further
participate
9 lost to follow up
220 included in intention-
to-treat analysis 
214 included in intention-
to-treat analysis 
82 did not reach last follow up†
1 neonatal death
54 did not attend
20 declined to further
participate
6 lost to follow up
1 withdrawn by clinician
128 reached last follow-up† 132 reached last follow-up† 
2 not analysed
2 terminations of pregnancy
223 allocated placebo
222 received treatment
1 withdrew before
treatment
226 allocated to metformin
225 received treatment
1 withdrew before
treatment
11 not analysed
2 stillbirths
4 miscarriages
1 termination of pregnancy
3 withdrew after treatment
issued
1 lost to follow-up
449 randomly assigned 
4867 participants screened for eligibility 
4418 excluded
2872 declined
730 ineligible
752 uncontactable
56 for other reasons*
8 did not attend appointment
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detect a diﬀ erence in mean birthweight percentile of 
SD 0·33 (equivalent to the diﬀ erence between a placebo 
mean of 4·0 kg18 and a metformin mean of 3·8 kg) at a 
two-sided 5% signiﬁ cance level with a two-group t test. 
We initially aimed to randomise 400 women based on 
anticipated high compliance and follow-up rates, but in a 
protocol amendment increased our sample size to 
450 women when anecdotal evidence (without formal 
testing) suggested that compliance was lower than 
anticipated.
We did our primary analysis in the modiﬁ ed intention-
to-treat population. We also did per-protocol analyses, in 
which we compared outcomes amongst participants who 
were compliant with treatment. Compliance was 
determined before review of the data or unmasking. To 
measure compliance we calculated the number of weeks 
from randomisation to delivery for each woman; 
participants reporting (via their study diary) that they 
took at least one tablet on at least 4 days per week for at 
least half of those weeks were deemed to have been 
compliant. We did not use plasma metformin to measure 
compliance as no such measure of compliance could be 
done for placebo.
We did exploratory analyses of secondary outcomes. No 
formal adjustment was made to any p values to allow for 
the large number of secondary endpoints analysed, and 
thus p values for secondary analyses need to be 
interpreted conservatively. We also did post-hoc analyses 
of safety outcomes of all reported serious adverse events 
and the combined adverse outcome of stillbirth, neonatal 
death, termination of pregnancy, or miscarriage.
We derived birthweight percentiles and Z scores of 
birthweight percentiles (livebirths only) for each patient 
after adjustment for sex, gestational age, and parity 
(nulliparous vs multiparous) with population-derived 
charts.19 We used a linear regression model adjusted for 
treatment centre and BMI band (30–39 vs ≥40 kg/m²) to 
compare Z scores between the groups and to obtain the 
adjusted mean diﬀ erence with 95% CI. This method was 
also used for other continuous outcomes including 
glucose and insulin and homeostatic model assessment 
of insulin resistance (HOMA-IR). When necessary, we 
did log transformations to achieve normal distribution 
of data before statistical testing. For assessment of CRP 
con centration in the umbilical cord, we used Kruskal–
Wallis one-way analysis of variance because this variable 
could not be transformed into a normal distribution. We 
used unadjusted logistic regression for binary outcomes 
and Fisher’s exact test when the event counts were small. 
Relevant denominators were either all participants 
randomised for whom information was available, or 
those having a livebirth for whom information was 
available.
We did analyses with SAS (version number 9.3). A trial 
steering and a data and safety monitoring committee 
oversaw the study. The trial was registered, ISRCTN 
number 51279843.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication.
Results
Between Feb 3, 2011, and Jan 16, 2014, inclusive, we randomly 
assigned 449 participants to the placebo group (n=223) or the 
metformin group (n=226), of whom 434 (97%) were included 
in the modiﬁ ed intention-to-treat analysis (ﬁ gure). The most 
common reasons for non-participation were a concern that 
study drugs might be harmful to the baby, and low awareness 
about the adverse eﬀ ects of obesity on pregnancy outcome. 
Baseline demo graphics, medical history, and maternal 
anthropometry were similar between groups (table 1).
Placebo group Metformin group
Mean (SD) 
or n (%)
N Mean (SD) 
or n (%)
N
Demographics and lifestyle
Age (years) 28·9 (5·1) 223 28·7 (5·8) 226
Currently smokes 31 (14%) 223 40 (18%) 226
Currently drinks alcohol 9 (4%) 223 3 (1%) 226
Illicit drug use 1 (<1%) 223 0 226
Highest educational qualiﬁ cation
School for ≤16 years 79 (35%) 223 75 (33%) 226
School for ≥16 years 144 (65%) 223 151 (67%) 226
At least one previous pregnancy ≥12 weeks’ gestation 161 (73%) 220 147 (65%) 226
Systolic blood pressure (mm Hg) 119·4 (10·4) 223 117·6 (10·8) 226
Diastolic blood pressure (mm Hg) 68·9 (7·3) 223 68·0 (7·8) 226
Gestation at baseline (days) 98·9 (8·7) 223 99·1 (8·1) 226
Medical history
Pre-eclampsia or pregnancy induced hypertension 7 (3%) 223 10 (4%) 226
Pre-pregnancy hypertension requiring treatment 2 (1%) 223 1 (<1%) 226
Polycystic ovary syndrome 21 (9%) 223 28 (12%) 226
Depression requiring treatment 71 (32%) 223 48 (21%) 226
Anxiety requiring treatment 20 (9%) 223 15 (7%) 226
Family history
Cardiovascular disease 69 (31%) 223 71 (31%) 226
Pre-eclampsia 22 (10%) 223 19 (8%) 226
Diabetes 101 (45%) 223 99 (44%) 226
Other 96 (43%) 223 109 (48%) 226
Anthropometry
Height (cm) 165·1 (5·9) 223 165·5 (5·9) 226
Weight (kg) 102·9 (17·0) 223 103·6 (15·5) 226
BMI (kg/m²) 37·7 (5·6) 223 37·8 (4·9) 226
Waist (cm) 108·7 (13·5) 222 110·1 (11·9) 225
Hip (cm) 126·4 (12·1) 222 127·4 (11·8) 225
Mid-arm (cm) 36·3 (5·0) 220 36·7 (4·7) 221
Mid-thigh (cm) 64·1 (7·7) 219 64·2 (6·9) 222
Tricep skinfold (mm) 31·2 (9·7) 222 31·9 (10·8) 222
Bicep skinfold (mm) 25·7 (10·0) 222 27·4 (10·9) 222
(Table 1 continues on next page)
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From diary returns and analysis with predeﬁ ned 
criteria, 118 (67%) of 177 women in the placebo group and 
109 (65%) of 167 women in the metformin group were 
deemed compliant. Subsequent analysis of metformin 
concentrations showed that detectable concentrations 
were present in the blood of 80 (61%) of 131 women in 
the metformin group who gave a blood sample at 
36 weeks’ gestation. To explore dosage, we identiﬁ ed the 
proportion of drug-taking days when 2500 mg or 2000 mg 
of study drug was taken. In the placebo group, for 56% of 
all possible tablet-taking days, the top dose of 2500 mg 
was taken, and for 68% of these days a dose of 2000 mg 
or more was taken; the corresponding values in the 
metformin group were 38% and 62%, respectively.
Mean birthweight at delivery was 3463 g (SD 660) in 
the placebo group and 3462 g (548) in the metformin 
group (table 2). Mean birthweight percentile was high in 
both groups (table 2); the proportion of liveborn babies 
weighing more than the 90th percentile was similar 
between the placebo group and the metformin group 
(38 [17%] of 220 and 31 [14%] of 214 babies, respectively). 
The primary outcome of Z score of birthweight percentile 
for babies liveborn at 24 weeks or more of gestation, 
standardised for sex, parity and gestation at delivery, was 
similar between the metformin and placebo groups, and 
the estimated eﬀ ect size of metformin on the primary 
outcome was non-signiﬁ cant (table 2).
We recorded no evidence of a reduction in the main 
secondary outcome of HOMA-IR at 36 weeks’ gestation, 
nor any evidence of a clinically or statistically signiﬁ cant 
eﬀ ect of metformin on fasting or 2 h glucose (after a 75 g 
oral glucose challenge) or fasting insulin at 36 weeks’ 
gestation (table 3). By contrast, fasting glucose and 
HOMA-IR score at 28 weeks’ gestation was lower in 
women in the metformin group than in those in the 
placebo group (appendix). Metformin had no signiﬁ cant 
eﬀ ect on the anthropometric variables of maternal weight 
gain in pregnancy or neonatal ponderal index (table 3).
Plasma IL-6 and CRP concentrations were both 
signiﬁ cantly lower in women given metformin, but no 
diﬀ erences were shown in other biochemical outcomes 
(table 3). Metformin did not seem to prevent gestational 
diabetes, as proportions of women fulﬁ lling either 
IADSPG (table 4) or WHO (data not shown) criteria for 
gestational diabetes at any time in pregnancy were similar 
between the two groups (table 4). Furthermore, metformin 
did not delay the onset of gestational diabetes (IADPSG 
criteria): 26 women in the placebo group were diagnosed 
at 28 weeks’ gestation and ten women were diagnosed at 
36 weeks compared with 11 women diagnosed at 28 weeks 
and 15 women at 36 weeks in the metformin group 
(p=0·0718, Mantel-Haenszel χ²; post-hoc analysis).
Maternal symptoms of diarrhoea and vomiting were 
more common in women in the metformin group 
(table 4). The incidence of other adverse outcomes, 
including preterm birth and low birthweight, caesarean 
section, and postpartum haemorrhage were similar in 
the two groups (table 4). We recorded no adverse eﬀ ects 
of metformin in post-hoc safety analyses comparing the 
proportion of women with a recordable serious adverse 
event between the two groups (table 4). The increase 
in the combined adverse outcome of miscarriage, 
termination of pregnancy, stillbirth or neonatal death in 
women in the metformin group was not signiﬁ cant 
(table 2). Admission to the neonatal unit was less 
common in the metformin group than the placebo group 
(table 4). We noted no diﬀ erences in outcomes at other 
timepoints between the two groups (appendix), with the 
exception of fasting glucose and HOMA-IR score, as 
mentioned above.
Further analyses of the data on a per-protocol basis 
resulted in similar ﬁ ndings to the modiﬁ ed intention-to-
treat analysis, with the exception of vomiting and CRP 
concentration, in which the direction of diﬀ erences was 
maintained but the results were no longer signiﬁ cant 
(appendix), and in 2 h glucose (estimated mean 
Placebo group Metformin group
Mean (SD) 
or n (%)
N Mean (SD) 
or n (%)
N
(Continued from previous page)
Subscapular skinfold (mm) 32·0 (12·2) 222 32·6 (11·8) 220
Maternal fat (%)* 46·8 (5·6) 48 48·2 (5·2) 53
Blood tests
Fasting glucose (mmol/L) 4·39 (0·34) 223 4·41 (0·40) 226
2 h glucose (mmol/L)† 5·50 (1·09) 223 5·20 (1·08) 226
Fasting insulin (pmol/L) 153·35 (70·84) 189 152·44 (85·15) 188
HOMA-IR score‡ 4·36 (2·16) 189 4·36 (2·76) 188
C-reactive protein (mg/L) 11·1 (7·4) 221 10·7 (6·9) 223
Cholesterol (mmol/L) 4·87 (1·15) 216 4·88 (1·09) 214
HDL (mmol/L) 1·67 (0·39) 215 1·64 (0·38) 214
LDL (mmol/L) 2·91 (0·78) 194 2·89 (0·86) 191
Triglycerides (mmol/L) 1·51 (0·53) 216 1·43 (0·56) 214
Interleukin-6 (mmol/L) 2·77 (5·50) 189 2·63 (4·37) 188
Leptin (ng/mL) 93·6 (42·1) 189 98·5 (40·3) 188
Serum cortisol (nmol/L) 396·4 (143·6) 189 431·0 (178·8) 188
NEFA (mmol/L) 0·52 (0·20) 189 0·48 (0·18) 188
PAI-1 to PAI-2 ratio 1·48 (1·39) 131 1·77 (5·22) 128
Putative father details
Height (cm) 178·5 (8·3) 204 177·1 (13·7) 202
Weight (kg) 92·3 (22·5) 187 93·5 (25·8) 188
Ethnic origin
White 214 (96%) 223 210 (94%) 224
Mixed 4 (2%) 223 4 (2%) 224
Asian 0 223 3 (1%) 224
Black 4 (2%) 223 6 (3%) 224
Chinese 0 223 0 224
Other 1 (<1%) 223 1 (<1%) 224
HOMA-IR= homeostatic model assessment of insulin resistance. NEFA=non-esteriﬁ ed fatty acids. PAI=plasminogen 
activator inhibitor. *Measured only in Edinburgh participants. †After a 75 g oral glucose challenge. ‡Fasting glucose 
(mmol/L) x insulin (μIU/L).
Table 1: Baseline characteristics
See Online for appendix
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Placebo group Metformin group Adjusted mean diﬀ erence 
or OR (95 % CI)
p value
Mean (SD) or n (%) N Mean (SD) or n (%) N
Primary outcome
Z score of birthweight percentile* 0·2680 (1·0055) 220 0·2464 (1·0179) 214 –0·029 (–0·217 to 0·158) 0·76
Birth outcome (all births)
Livebirth at ≥24 weeks’ gestation 220 (99%) 222 214 (97%) 221 ·· ··
Stillbirth at ≥24 weeks’ gestation, miscarriage, or 
termination of pregnancy
2 (1%)† 222 7 (3%)‡ 221 3·597 (0·739 to 17·504)§ 0·11
Birth outcome (liveborn babies at ≥24 weeks’ gestation)
Gestational age at delivery (days) 275·9 (15·9) 220 276·6 (11·7) 214 ·· ··
Male sex 109 (50%) 220 109 (51%) 214 ·· ··
Birthweight at delivery (g) 3463 (660) 220 3462 (548) 214 ·· ··
Birthweight percentile 57·3 (27·9) 220 56·9 (28·6) 214 ·· ··
OR=odds ratio. *Percentile by gestational age, sex, and parity for livebirths at ≥24 weeks’ gestation. †Two terminations of pregnancy, one for fetal abnormality (split hand 
and foot syndrome) and one after a spontaneous membrane rupture at 18 weeks’ gestation. ‡Of the two stillbirths, one was at 31 weeks of a baby with a known cardiac 
anomaly and severe hydrops fetalis and one was an intrauterine death of a normally formed baby born at 38 weeks with a birthweight less than the third percentile for 
gestation. Of the four miscarriages, one was after a road traﬃ  c accident and three were spontaneous. One termination of pregnancy was done after a diagnosis of trisomy 21. 
None of the women returned diaries nor provided a blood sample for analysis of metformin. §OR from post-hoc analysis.
Table 2: Primary and birth outcomes 
Placebo group Metformin group Adjusted mean diﬀ erence 
or ratio (95% CI)
p value
Mean (SD) N Mean (SD) N
Maternal biochemistry at 36 weeks’ gestation
Fasting glucose (mmol/L) 4·42 (0·48) 151 4·35 (0·45) 143 –0·060 (–0·163 to 0·043) 0·25
2 h glucose (mmol/L)* 5·96 (1·46) 148 5·70 (1·32) 142 –0·251 (–0·565 to 0·062) 0·12
Fasting insulin (pmol/L) 208·98 (91·12) 131 227·73 (170·50) 127 1·005 (0·901 to 1·120) 0·93
HOMA-IR score † 5·98 (2·89) 131 6·30 (4·78) 123 0·974 (0·865 to 1·097) 0·67
C-reactive protein (mg/L) 9·20 (7·10) 150 7·47 (4·62) 140 0·860 (0·743 to 0·996) 0·04
Cholesterol (mmol/L) 6·32 (1·44) 144 6·33 (1·74) 139 1·004 (0·954 to 1·056) 0·88
HDL (mmol/L) 1·70 (0·38) 145 1·76 (0·43) 138 0·051 (–0·040 to 0·142) 0·27
LDL (mmol/L) 3·57 (1·13) 126 3·77 (1·25) 118 1·064 (0·982 to 1·152) 0·13
Triglycerides (mmol/L) 2·79 (0·84) 146 2·76 (0·88) 140 0·993 (0·926 to 1·064) 0·83
Interleukin-6 (mmol/L) 3·86 (4·10) 131 2·93 (1·37) 127 0·847 (0·754 to 0·952) 0·01
Leptin (ng/mL) 105·0 (52·4) 131 106·6 (58·8) 127 1·005 (0·902 to 1·120) 0·93
Serum cortisol (nmol/L) 821·7 (232·9) 131 867·0 (225·5) 127 1·062 (0·999 to 1·128) 0·05
NEFA (mmol/L) 0·47 (0·18) 131 0·46 (0·19) 127 0·947 (0·859 to 1·044) 0·27
PAI-1 to PAI-2 ratio 3·20 (2·61) 131 2·97 (2·79) 128 0·913 (0·771 to 1·081) 0·29
Cord-blood biochemical outcomes
Glucose (mmol/L) 3·89 (1·24) 79 4·06 (1·08) 74 1·067 (0·974 to 1·170) 0·16
Insulin (pmol/L) 76·05 (52·02) 47 79·24 (61·12) 57 1·060 (0·767 to 1·463) 0·72
HOMA-IR score† 1·92 (1·39) 38 1·91 (2·00) 41 1·012 (0·701 to 1·462) 0·95
C-reactive protein (mg/L)‡ 4·32 (19·55) 78 2·36 (2·29) 73 ·· 0·74
Anthropometric variables
Maternal weight gain during pregnancy (kg) 7·23 (4·91) 156 6·70 (6·00) 143 –0·680 (–1·863 to 0·503) 0·26
Ponderal index (mass [g]/height3 [cm])§ 2·60 (0·41) 143 2·67 (0·50) 130 1·032 (0·996 to 1·069) 0·08
 All variables, except for maternal glucose and HDL, and neonatal C-reactive protein, were log-transformed for the statistical analysis and converted back to original scale for 
this table. HOMA-IR=homeostatic model assessment of insulin resistance. NEFA=non-esteriﬁ ed fatty acids. PAI=plasminogen activator inhibitor. *After a 75 g oral glucose 
challenge. †Fasting glucose (mmol/L) x insulin (μIU/L)/22·5. ‡Kruskal–Wallis non-parametric test used. §Livebirths only; we removed outliers outside SD 6 and 
log-transformed data for the statistical analysis; results were back-transformed for this table.
Table 3: Secondary outcomes 
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diﬀ erence –0312 mmol/L, 95% CI –0·620 to –0·004; 
p=0·0471) and fasting insulin (6·04 pmol/L, 5·40–6·78; 
p=0·0173) at 28 weeks’ gestation, which were 
signiﬁ cantly lower in the metformin group than in the 
placebo group.
Discussion
To our knowledge, EMPOWaR is the ﬁ rst trial of a 
pharmacological intervention to reduce the risk of ill 
health in later life, using birthweight as a surrogate 
marker, in the oﬀ spring of obese pregnant women. By 
contrast with our original hypothesis, metformin given 
at a median dose of 2000 mg daily to obese and severely 
obese pregnant women (mean BMI 37·7 kg/m²) without 
diabetes, from 12–16 weeks’ gestation until delivery, had 
no eﬀ ect on birthweight or neonatal or maternal 
anthropometry. On the basis of the study being powered 
to detect a clinically meaningful eﬀ ect size, we conclude 
that this ﬁ nding shows a true absence of eﬀ ect of 
metformin on birthweight rather than a type 2 error. The 
absence of eﬀ ect was apparent in both intention-to-treat 
and per-protocol analyses. We conclude that metformin 
does not have a role in reducing the birthweight of 
oﬀ spring of obese pregnant women.
The strengths of this study are its multicentre 
randomised controlled design, making the study robust 
and generalisable, and that, despite women’s natural 
reluctance to take medication during pregnancy, we were 
able to recruit to our target sample size, generating 
adequate power to address our hypothesis.
Although compliance was lower than anticipated, this 
was balanced by the SD for birthweight also being lower. 
As such, the 95% CI for the primary comparison in both 
the intention-to-treat and per-protocol analyses both 
exclude the prespeciﬁ ed minimum clinically relevant 
eﬀ ect size of 0·33. We conclude that the failure to detect 
a signiﬁ cant diﬀ erence between the groups is a strong 
negative ﬁ nding rather than a result of the trial being 
underpowered.
Studies of other interventions aimed at reducing 
birthweight in obese pregnant women, including diet 
and lifestyle interventions,20–22 have likewise shown no 
signiﬁ cant eﬀ ects. Our data showing that metformin has 
no eﬀ ect on birthweight in obese and severely obese 
Placebo group Metformin group OR (95% CI) p value
Women or their babies with a recorded serious adverse event 41/222 (18%) 37/225 (16%) 0·869 (0·533–1·417) 0·57
Maternal delivery and postnatal
Any caesarean section in index pregnancy 76/222 (34%)  65/219 (30%) 0·811  (0·543–1·211)* 0·31
Primary caesarean section 46/222 (21%) 42/219 (19%) 0·908 (0·569–1·449) 0·69
Postpartum haemorrhage >1000 mL 21/216 (10%) 20/212 (9%) 0·967 (0·508–1·842) 0·92
Preterm birth† 14/220 (6%) 18/214 (8%) 1·345 (0·651–2·777) 0·47
Development of gestational diabetes‡ 36/153 (24%) 26/142 (18%) 0·728 (0·414–1·283) 0·27
Pregnancy induced hypertension 14/222 (6%) 21/221 (10%) 1·56 (0·772–3·152) 0·22
Pre-eclampsia 3/222 (1%) 7/221 (3%) 2·39 (0·61–9·36) 0·21
Fetal and neonatal outcomes (livebirths only)
Admission to the neonatal unit 29/219 (13%) 14/213 (7%) 0·461 (0·236–0·899)* 0·02
Congenital anomaly 8/217 (4%) 7/209 (3%) 0·905 (0·322–2·543) 0·85
Neonatal death in the delivery room 0/220 0/214 ·· ··
Neonatal death at a later stage 2/220 (1%) 1/214 (<1%) ·· 1·00*§
Incidence of low birthweight <10th percentile 11/220 (5%) 14/214 (7%) 1·330 (0·590–2·999) 0·49
Incidence of low birthweight <3rd percentile 3/220 (1%) 3/214 (1%) ·· 1·00§
Maternal symptoms up to 36 weeks’ gestation¶
Taste disturbance 32/198 (16%) 25/199 (13%) 0·745 (0·424–1·311) 0·31
Skin reactions 39/198 (20%) 36/199 (18%) 0·900 (0·545–1·489) 0·68
Abdominal pain 42/198 (21%) 49/199 (25%) 1·213 (0·759–1·940) 0·42
Flatulence 44/198 (22%) 51/199 (26%) 1·206 (0·760–1·915) 0·43
Constipation 57/198 (29%) 57/199 (29%) 0·993 (0·643–1·534) 0·98
Diarrhoea 37/198 (19%) 83/199 (42%) 3·113 (1·975–4·908) <0·0001
Nausea 79/198 (40%) 97/199 (49%) 1·432 (0·962–2·132) 0·08
Vomiting 43/198 (22%) 63/199 (32%) 1·670 (1·064–2·621) 0·03
Headache 66/198 (33%) 65/199 (33%) 0·970 (0·638–1·474) 0·89
Data are n/N (%), unless otherwise indicated. OR=odds ratio. *Post-hoc analysis. †Livebirths only; four (29%) of 14 preterm births in the placebo group and three (17%) of 18 in 
the metformin group were spontaneous preterm births after preterm labour. ‡International Association of Diabetes and Pregnancy Study Groups criteria: fasting glucose of 
5·1 mmol/L or more or 2 h glucose of 8·5 mmol/L or more at either 28 or 36 weeks. §Fisher’s exact test reported. ¶For all symptoms, categories are none, mild, moderate, or 
severe. If a participant had any mild, moderate, or severe symptom at any time, this was recorded as “yes” for presence of maternal symptoms.
Table 4: Adverse outcomes 
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pregnant women are in line with secondary outcome 
data from a smaller study of metformin in non-obese 
(mean 29·5 kg/m² [SD 7·0]) pregnant women with a 
history of polycystic ovary syndrome.23 We are aware of 
two other ongoing studies of the eﬀ ect of metformin in 
obese pregnant women (Clinicaltrials.gov, number 
NCT01273584 and Australian New Zealand Clinical Trials 
registry, ACTRN 12612001277831).
We believe that metformin had its expected 
pharmacodynamic eﬀ ects. Fasting glucose and insulin 
were lower in the metformin group than the placebo 
group at 28 weeks in the intention-to-treat analysis, and 
fasting and 2 h glucose, insulin, and HOMA-IR were 
lower in the metformin group at 28 weeks in the per-
protocol analysis. The subsequent lack of eﬀ ect of 
metformin at 36 weeks is initially surprising, but might 
indicate changes in glucose homoeostasis throughout 
pregnancy in obese women.
Although metformin had no eﬀ ect on the primary 
outcome, the metformin-associated reduction in 
inﬂ ammatory markers CRP and IL-6 might be beneﬁ cial. 
These markers are found at higher concentrations in 
obese pregnant women than in pregnant women of a 
normal weight19 and have been associated with adverse 
outcomes such as preterm birth and pre-eclampsia.24,25 
Our ﬁ ndings are consistent with those in non-pregnant 
individuals, in whom metformin reduces concentrations 
of CRP26 and (variably) IL-6.27
Absence of eﬃ  cacy of metformin in reducing mean 
birthweight, despite lowering maternal glucose and 
insulin in mid-pregnancy, casts doubt on the 1952 
Pedersen hypothesis28 that maternal hyperglycaemia 
drives fetal hyperglycaemia, and hence fetal hyper-
insulinaemia and fetal overgrowth. Other investigators 
have hypothesised, by contrast with Pedersen, that excess 
maternal lipids might be as, or even more important 
than, excess maternal glucose in fetal fat accumulation, 
particularly in the presence of maternal obesity.29 The 
present study provides the ﬁ rst experimental evidence 
that factors other than maternal glucose are important in 
fetal overgrowth, challenging conventional thinking 
about the factors linking maternal obesity and oﬀ spring 
macrosomia.
Metformin might have a beneﬁ cial eﬀ ect on future life 
risk of obesity and metabolic syndrome in oﬀ spring, 
even in the absence of an eﬀ ect on birthweight 
percentile. In an animal study,30 prenatal metformin 
improved glucose tolerance, and reduced accumulation 
of body weight, and fat mass in adulthood of the 
oﬀ spring, despite having only marginal eﬀ ects on 
birthweight. Additionally, in the Metformin in 
Gestational diabetes (MiG) study,31 children of women 
randomised to the metformin group had lower visceral 
body fat at 2 years than did children of women 
randomised to insulin, despite similarities in birth-
weight. Further follow-up of babies born to mothers in 
the EMPOWaR trial is planned to explore this possibility 
and will identify longer-term outcomes on oﬀ spring of 
obese women given metformin in pregnancy. In the 
meantime, metformin should not be used to improve 
pregnancy outcomes in obese women.
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